The choice of a second-line agent depends on co-morbidities, primarily CV and renal disease.

People with type 2 diabetes requiring a second-line glucose-lowering agent

Select the second-line agent according to comorbidities, especially cardiovascular and kidney disease

Not explicitly stated

Individualized therapy and reduced cardiorenal risk